Report says COVID-19 patients respond to Gilead’s remdesivir, shares surge
(Reuters) – Gilead Sciences Inc’s shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug … Read More
